1
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Pietrantonio F, Petrelli F, Coinu A, Di
Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi
I, Lonati V, et al: Predictive role of BRAF mutations in patients
with advanced colorectal cancer receiving cetuximab and
panitumumab: A meta-analysis. Eur J Cancer. 51:587–594. 2015.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Tauriello DVF and Batlle E: Targeting the
microenvironment in advanced colorectal cancer. Trends Cancer.
2:495–504. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Moriarity A, O'Sullivan J, Kennedy J,
Mehigan B and McCormick P: Current targeted therapies in the
treatment of advanced colorectal cancer: A review. Ther Adv Med
Oncol. 8:276–293. 2016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Schmeel FC, Simon B, Sabet A, Luetkens JA,
Träber F, Schmeel LC, Ezziddin S, Schild HH and Hadizadeh DR:
Diffusion-weighted magnetic resonance imaging predicts survival in
patients with liver-predominant metastatic colorectal cancer
shortly after selective internal radiation therapy. Eur Radiol.
27:966–975. 2017. View Article : Google Scholar : PubMed/NCBI
|
7
|
van Hazel GA, Heinemann V, Sharma NK,
Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland
AH, Ferguson T, et al: SIRFLOX: Randomized phase III trial
comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus
mFOLFOX6 (plus or minus bevacizumab) plus selective internal
radiation therapy in patients with metastatic colorectal cancer. J
Clin Oncol. 34:1723–1731. 2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Mohammadi A, Mansoori B and Baradaran B:
The role of microRNAs in colorectal cancer. Biomed Pharmacother.
84:705–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Tsukamoto M, Iinuma H, Yagi T, Matsuda K
and Hashiguchi Y: Circulating exosomal microRNA-21 as a biomarker
in each tumor stage of colorectal cancer. Oncology. 92:360–370.
2017. View Article : Google Scholar : PubMed/NCBI
|
10
|
Tang W, Wan S, Yang Z, Teschendorff AE and
Zou Q: Tumor origin detection with tissue-specific miRNA and DNA
methylation markers. Bioinformatics. 34:398–406. 2018. View Article : Google Scholar : PubMed/NCBI
|
11
|
Mansoori B, Mohammadi A, Ghasabi M,
Shirjang S, Dehghan R, Montazeri V, Holmskov U, Kazemi T, Duijf P,
Gjerstorff M, et al: miR-142-3p as tumor suppressor miRNA in the
regulation of tumorigenicity, invasion and migration of human
breast cancer by targeting Bach-1 expression. J Cell Physiol.
234:9816–9825. 2019. View Article : Google Scholar : PubMed/NCBI
|
12
|
Li Z, Yu X, Shen J, Law PT, Chan MT and Wu
WK: MicroRNA expression and its implications for diagnosis and
therapy of gallbladder cancer. Oncotarget. 6:13914–13921.
2015.PubMed/NCBI
|
13
|
Hu JL, He GY, Lan XL, Zeng ZC, Guan J,
Ding Y, Qian XL, Liao WT, Ding YQ and Liang L: Inhibition of
ATG12-mediated autophagy by miR-214 enhances radiosensitivity in
colorectal cancer. Oncogenesis. 7:162018. View Article : Google Scholar : PubMed/NCBI
|
14
|
Penna E, Orso F and Taverna D: miR-214 as
a key hub that controls cancer networks: Small player, multiple
functions. J Invest Dermatol. 135:960–969. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ling H, Pickard K, Ivan C, Isella C, Ikuo
M, Mitter R, Spizzo R, Bullock M, Braicu C, Pileczki V, et al: The
clinical and biological significance of miR-224 expression in
colorectal cancer metastasis. Gut. 65:977–989. 2016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Fernandez S, Risolino M, Mandia N, Talotta
F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P:
miR-340 inhibits tumor cell proliferation and induces apoptosis by
targeting multiple negative regulators of p27 in non-small cell
lung cancer. Oncogene. 34:3240–3250. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Fang F, Chang RM, Yu L, Lei X, Xiao S,
Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell
proliferation and metastasis by directly targeting FGF5 in
hepatocellular carcinoma. J Hepatol. 63:874–885. 2015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Lima CR, Geraldo MV, Fuziwara CS, Kimura
ET and Santos MF: MiRNA-146b-5p upregulates migration and invasion
of different papillary thyroid carcinoma cells. BMC Cancer.
16:1082016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Liao J, Liu R, Shi YJ, Yin LH and Pu YP:
Exosome-shuttling microRNA-21 promotes cell migration and
invasion-targeting PDCD4 in esophageal cancer. Int J Oncol.
48:2567–2579. 2016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Guo X, Han T, Hu P, Guo X, Zhu C, Wang Y
and Chang S: Five microRNAs in serum as potential biomarkers for
prostate cancer risk assessment and therapeutic intervention. Int
Urol Nephrol. 50:2193–2200. 2018. View Article : Google Scholar : PubMed/NCBI
|
21
|
Wang Q, Zhang H, Shen X and Ju S: Serum
microRNA-135a-5p as an auxiliary diagnostic biomarker for
colorectal cancer. Ann Clin Biochem. 54:76–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhu X, Han S, Wu S, Bai Y, Zhang N and Wei
L: Dual role of twist1 in cancer-associated fibroblasts and tumor
cells promoted epithelial-mesenchymal transition of esophageal
cancer. Exp Cell Res. 375:41–50. 2019. View Article : Google Scholar : PubMed/NCBI
|
23
|
Musavi Shenas MH, Eghbal-Fard S,
Mehrisofiani V, Abd Yazdani N, Rahbar Farzam O, Marofi F and
Yousefi M: MicroRNAs and signaling networks involved in
epithelial-mesenchymal transition. J Cell Physiol. 234:5775–5785.
2019. View Article : Google Scholar : PubMed/NCBI
|
24
|
Dong H, Weng C, Bai R, Sheng J, Gao X, Li
L and Xu Z: The regulatory network of miR-141 in the inhibition of
angiogenesis. Angiogenesis. 22:251–262. 2019. View Article : Google Scholar : PubMed/NCBI
|
25
|
Bedke J, Heide J, Ribback S, Rausch S, de
Martino M, Scharpf M, Haitel A, Zimmermann U, Pechoel M, Alkhayyat
H, et al: Microvascular and lymphovascular tumour invasion are
associated with poor prognosis and metastatic spread in renal cell
carcinoma: A validation study in clinical practice. BJU Int.
121:84–92. 2018. View Article : Google Scholar : PubMed/NCBI
|
26
|
Casasent AK, Schalck A, Gao R, Sei E, Long
A, Pangburn W, Casasent T, Meric-Bernstam F, Edgerton ME and Navin
NE: Multiclonal invasion in breast tumors identified by topographic
single cell sequencing. Cell. 172:205–217.e12. 2018. View Article : Google Scholar : PubMed/NCBI
|
27
|
Zheng Y, Li S, Boohaker RJ, Liu X, Zhu Y,
Zhai L, Li H, Gu F, Fan Y, Lang R, et al: A microRNA expression
signature in taxane-anthracycline-based neoadjuvant chemotherapy
response. J Cancer. 6:671–677. 2015. View Article : Google Scholar : PubMed/NCBI
|